First Manhattan CO Cytom X Therapeutics, Inc. Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $2.24 Million - $2.73 Million	-345,451 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$6.55 - $8.83 $2.01 Million - $2.71 Million	-307,105 Reduced 47.06%	345,451 $2.3 Million
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $1.05 Million - $2.08 Million	-142,368 Reduced 17.91%	652,556 $5.44 Million
Q1 2020 May 06, 2020	SELL	$3.61 - $8.6 $664,016 - $1.58 Million	-183,938 Reduced 18.79%	794,924 $6.1 Million
Q4 2019 Feb 13, 2020	BUY	$5.17 - $8.91 $5.06 Million - $8.72 Million	978,862 New	978,862 $8.13 Million
Q2 2019 Aug 16, 2019	SELL	$9.35 - $11.41 $3.01 Million - $3.67 Million	-322,000 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$9.5 - $19.16 $3.06 Million - $6.17 Million	322,000 New	322,000 $3.46 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.